You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations, except those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Click “OK” to confirm you are a Healthcare Professional.
Clinical evidence demonstrates industry-leading hemodynamics
The Medtronic transcatheter aortic valve with a self-expanding, supra-annular design delivers industry-leading hemodynamics. See the recently released clinical evidence on our newest generation TAVI device as well as longer-term hemodynamic performance out to 5 years.
A large EOA (eﬀective orifce area) reduces the likelihood of PPM (patient-prosthesis mismatch). Choose Evolut™ TAVI for larger EOAs — allowing patients to maintain a higher exercise capacity.1,2
Corevalve™ U.S. Pivotal high risk trial 5 years follow up randomized trial
At 5-year mark, a significantly better hemodynamic performance was sustained for CoreValve™ TAVI system over SAVR with less structural valve deterioration* than SAVR11,13.
Surtavi 5 years follow up
Consistently good outcomes CoreValve™ and Evolut™ TAVI platforms maintained hemodynamic benefts and stable valve performance at fve years in intermediate risk patients.
Evolut™ TAVI system still numerically better than SAVR for primary Endpoint of all-cause mortality and disabling stroke at two years.15
Primary endpoint was 4.3% for TAVI versus 6.3% for SAVR, TAVI was non inferior to surgery.
Hemodynamics were significantly better for TAVI at all time points.
Echocardiographic outcomes following TAVI with SAPIEN 3 23 mm TAV vs. Evolut™ 26 mm TAV16
SVD definition reference: Capodanno D, et al, Eur Heart J. 2017;38:3382-3390.
NYHA Class 3 or 4.
Bleiziffer S, Eichinger WB, Hettich I, et al. Impact of patient-prosthesis mismatch on exercise capacity in patients after bioprosthesis aortic valve replacement. Heart. May 2008;94(5):637-641.
Van Slooten YJ, van Melle JP, Freling HG, et al. Aortic valve prosthesis-patient mismatch and exercise capacity in adult patients with congenital heart disease. Heart. January 2016;102(2):107-113.
Hahn RT, Leipsic J, Douglas PS, et al. Comprehensive Echocardiographic Assessment of Normal Transcatheter Valve Function. JACC Cardiovasc Imaging. Published online June 8, 2018.
Pibarot P, Dumesnil JG, Jobin J, Cartier P, Honos G, Durand LG. Hemodynamic and physical performance during maximal exercise in patients with an aortic bioprosthetic valve: comparison of stentless versus stented bioprostheses. J Am Coll Cardiol. November 1, 1999;34(5):1609-1617.
Pibarot P, Dumesnil JG. Prosthesis-patient mismatch: definition, clinical impact, and prevention. Heart. August 2006;92(8):1022-1029.
Flameng W, Herregods MC, Vercalsteren M, Herijgers P, Bogaerts K, Meuris B. Prosthesis-patient mismatch predicts structural valve degeneration in bioprosthetic heart valves. Circulation. May 18, 2010;121(19):2123-2129.
Ruel M, Rubens FD, Masters RG, et al. Late incidence and predictors of persistent or recurrent heart failure in patients with aortic prosthetic valves. J Thorac Cardiosvasc Surg. January 2004;127(1):149-159.
Williams MR, Qiao H, Forrest JK, et al. 1-Year Outcomes With The Evolut PRO Self-Expanding Repositionable Transcatheter Aortic Valve With Pericardial Wrap. Presented at ACC Annual Scientific Session and Expo; March 10-12, 2018; Orlando, FL.
Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. April 6, 2017;376(14):1321-1331.
Grube, et al. 1-year Outcomes Following Real-world Transcatheter Aortic Valve Implantation with a Self-Expanding Repositionable Valve: Results from the FORWARD Study. Presented at EuroPCR 2018; Paris, France.
Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis. N Engl J Med. May 8, 2014;370(19):1790-1798.
Ribeiro HB, Lerakis S, Gilard M, et al. Transcatheter Aortic Valve Replacement in Patients With Low-Flow, Low-Gradient Aortic Stenosis: The TOPAS-TAVI Registry. J Am Coll Cardiol. March 27, 2018 71(12):1297-1308.
Gleason TG, Reardon MJ, Popma JJ, et al. 5-Year Outcomes of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement in High-Risk Patients. J Am Coll Cardiol. 2018 December 2018;72(22):2687-2696.
Van Mieghem NM. 5-year clinical and echocardiographic outcomes from the randomized SURTAVI trial. Presented at TCT 2021; November 5, 2021; Orlando, FL.
John K. Forrest, M.D. on behalf of the Evolut Low Risk Investigators. The Evolut Low Risk Trial Complete 2-year Follow-up. Presented at EuroPCR 2021.
Ring ME, et al. Comparison of Echocardiographic Outcomes Following Transcatheter Aortic Valve Replacement with Edwards S3 23 mm versus Medtronic Evolut 26 mm Valves. Poster presented at ACC 2020.